After generics it’s the turn of biosimilar drugs, a budding market

9 septiembre 2014

Biosimilar drugs are the complex equivalents of generic ones and are destined to make a great impact on the healthcare system over the coming years. According to a researcher, ‘they are going to have an importance on a par with that of the introduction of generics.’ So it is necessary to set up a suitable regulatory framework, authors of a new study say.